PT Kalbe Farma Tbk., (KLBF) Fair Value & Analysis
Healthcare · ID · Market cap 30.3T IDR
Fair value as of: Jun 24, 2026
From 26 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from 1,394 IDR to 1,637 IDR (+17.5%) since Jun 23, 2026. Share price +2.1% over the past month.
Price vs Fair Value (12 months)
12‑month range 660.65 IDR – 1,541 IDR · fair‑value band 972.62 IDR – 2,224 IDR · the 760.00 IDR price screens below the 1,637 IDR fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
PT Kalbe Farma Tbk., (KLBF) currently trades at 760.00 IDR, while our model-based Fair Value estimate is 1,637 IDR — implying the stock looks roughly 115.4% undervalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.
Over the trailing twelve months, PT Kalbe Farma Tbk., generated revenue of 36.2T IDR at a net margin of 10.0%. Revenue grew 10.1% year over year. It earns a return on equity of 14.4%. The balance sheet holds a net cash position of 4.0T IDR. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
PT Kalbe Farma Tbk., reported revenue of 35.3T IDR in FY2025 versus 26.3T IDR in FY2021, a compound +7.7%/yr. Reported net income was 3.7T IDR in FY2025, compounding +3.6%/yr from FY2021.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,136 | $630.79 | -44% |
| Johnson & Johnson, JNJ | 4,128 MXN | 2,401 MXN | -42% |
| AbbVie Inc ABBV | $230.01 | $133.86 | -42% |
| Roche Holding ROGN | 7,050 MXN | 316.37 MXN | -96% |
| Merck & Co MRCK34 | R$76.74 | R$50.09 | -35% |
| AstraZeneca PLC A1ZN34 | R$159.89 | R$87.02 | -46% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is PT Kalbe Farma Tbk., (KLBF) undervalued?
What is the fair value of KLBF?
What is the quality score of KLBF?
What is the revenue of PT Kalbe Farma Tbk., (KLBF)?
What is the net profit margin of KLBF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.